
Impact of Inflation Reduction Act on Biosimilars
Article Summary – The Inflation Reduction Act (IRA), aimed at lowering the financial burden on people and cutting federal spending on drugs, could significantly impact the market dynamics for biosimilar drugs. The Act introduces several provisions, including direct price negotiations with manufacturers and higher reimbursement for biosimilars in Medicare Part











